JMP Securities maintains Cytokinetics stock with $78 target
JMP Securities reiterated its Market Outperform rating and $78.00 price target for Cytokinetics shares (NASDAQ:CYTK). This affirmation comes despite the stock experiencing a significant drop on ...
healthday33m
Pre-Op Immunotherapy May Help Treat Aggressive Breast Cancers
Giving patients with a common form of breast cancer an immunotherapy drug before surgery appears to boost outcomes, a n ...